Phase 4 N=135 Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment
Major Depression
Primary: Montgomery-Asberg's Depression Rating Scale — 9.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids
Keloid
Primary: Mean Change in Composite Observer Score for Patient and Observer Scar Assessment Scale (POSAS) — -9.5; -8.9 score on a scale
N/A N=23 Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
Stage IIA Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Change in Maximum SUV of Tumors Measured by FDG-PET Pre- and Post Receipt of Pazopanib Versus Placebo — -0.1; -0.1 Standardized uptake value-SUV — p=0.4
Phase 2 N=27 Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Objective Radiographic Tumor Response in Patients With Recurrent Solid Tumor Brain Metastases Treated With Bevacizumab — 2 Participants
N/A N=20 Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo
Tourette Disorder · Chronic Tic Disorder
Primary: Hopkins Motor/Vocal Tic Scale (HM/VTS) — 1.22; 0.70 score on a scale
Phase 2 N=58 Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Phase 2 N=16 Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
Glioblastoma Multiforme · Glioblastoma - Category
Primary: Overall Survival (OS) — 11.73 months
Phase 2 N=28 Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Acromegaly
Primary: Determination of the Maximum Tolerated Dose (MTD) by Number of Subjects With DLTs. — 0; 0; 0 participants
N/A N=90 The Use of Clear Aligners With Movement Enhancement Techniques
Malocclusion
Primary: Tooth Movement Change — 0.363 millimeters
Phase 3 N=138 A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
Depressive Disorder, Treatment-Resistant
Primary: Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Mixed-Effects Model Using…
N/A N=350 Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)
Coronary Artery Disease
Primary: MACE at 30 Days — 2.3; 3.1; 15 Percent probability of MACE
N/A N=60 Motivational Interviewing to Enhance Adherence of Patients With Psychogenic Non-epileptic Seizures
Psychogenic Non-epileptic Seizures, Motivational Interviewing
Primary: Adherence — 9; 17 Participants — p=0.015
Phase 3 N=238 A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period
Actinic Keratosis (AK)
Primary: Proportion of Subjects With Complete Clearance of AK Lesions at the End of Study Visit at 16 Weeks — 6; 9; 10; 7 Participants
Phase 4 N=78 Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
Osteogenesis Imperfecta
Primary: Spine Bone Mineral Density (BMD) — 6.1; 2.8 percentage of change in g/cm2
Early Phase 1 N=33 Aqueous Humor Dynamics and Brimonidine
Intraocular Pressure
Primary: Seated Day-time IOP 9 am and 11 am, Supine Day-time IOP 9 am and 11 am, and Seated Night-time IOP 9 pm and 11 pm — 18.1; 20.3; 18.0; 19.9 mmHg